Business
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Data recently presented at the Society for Neuro-Oncology (SNO) 27th Annual Meeting Preliminary results showcase updated patient population profile and safety
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Data recently presented at the Society for Neuro-Oncology (SNO) 27th Annual Meeting\nPreliminary results showcase updated patient population profile and safety\nContinued progress toward planned interim analysis when 30-50% of subjects are evaluable at 6 months after enrollment on the study, expected mid-year 2023\nHOUSTON, Dec. 8, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced preliminary results from its ongoing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM).\n\n \n \n \n \n \n \n\n \n\"Although data are still early, we are pleased with these results in terms of recruiting a balanced patient population to compare Berubicin to Lomustine in the treatment of GBM, which may highlight Berubicin's potential to provide a better therapeutic option for patients after first-line therapy for their disease. We remain steadfast in our efforts to drive patient enrollment across the U.S. and Europe and are making significant progress toward our planned interim analysis, which we expect to occur in mid-2023. Our team remains dedicated to moving this important program forward and to providing patients, families and physicians with a much needed treatment opportunity for this devastating disease,\" commented John Climaco, CEO of CNS Pharmaceuticals.\n\"Berubicin continues to demonstrate its ability to be an innovative treatment in GBM as a safe and potentially effective therapy. These preliminary findings bolster our conviction in Berubicin as we continue to advance this study forward. Based on the results we've seen preclinically and in the clinic thus far, we remain confident in Berubicin's potential to provide a consequential and much needed clinical benefit for GBM patients. We are making excellent progress with patient recruitment worldwide and, because we have currently described a balanced randomized population, we look forward to providing a meaningful comparison between Berubicin and what has been considered a standard of care for second line therapy (Lomustine),\" added Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals.\nThe preliminary res...